[S9.003] Bright Light Therapy Improves Excessive Daytime Sleepiness Associated with Parkinson's Disease
Aleksandar Videnovic,1Angelica Marconi,2Teresa Kuhta,2Scott Miskevics,3Phyllis Zee2
1Boston, MA, USA, 2Chicago, IL, USA, 3Hines, IL, USA
Objective: To examine safety and efficacy of light therapy (LT) for excessive daytime sleepiness (EDS) associated with PD.
Background: EDS frequently impairs quality of life and safety of PD patients. Treatment options are limited and associated with side effects. LT has not been systematically studied as a treatment for disturbed sleep/wake cycles in PD.
Design/Methods: Thirty PD participants (13M/17F, age 63.1±9.8yrs), H&Y stage 2-4, disease duration 6.9±4.3yrs, with EDS, defined as the Epworth Sleepiness Scale (ESS) score ≥10, and without a primary sleep disorder, were randomized to a treatment with bright light (5000 lux) or dim-red light (300 lux; control condition), twice daily, in one-hour sessions, during a two-week period. Participants were matched for PD medications, and remained on a stable medication regimen prior and throughout LT. EDS and sleep quality were assessed by the ESS, the Pittsburg Sleep Quality Index (PSQI), the Parkinson Disease Sleep Scale at the baseline, post-treatment (2 weeks) and two weeks after LT (4 weeks). Additional outcome measures included UPDRS, the Fatigue Severity Scale, the Beck Depression Inventory and the PDQ39 scale. Outcome measurements before and after LT were compared using the paired t-test.
Results: There were no significant baseline differences between two groups. LT was well tolerated. Reported side effects included transient watery eyes (n=4). Exposure to bright light was associated with significant improvements in EDS (p=0.001). ESS scores: 15.6±3.2 (baseline), 11.3±3.5 (2 weeks). There was a trend toward significant improvements in the UPDRS I score in the bright LT arm (p=0.592). Improvements in EDS persisted two weeks after the completion of bright LT (p=0.003). There was a trend toward significant improvements in sleep quality two weeks after completion of bight LT (p=0.067). There were no significant changes in other outcomes post LT.
Conclusions: LT is a safe, non-pharmacological intervention associated with improvements in EDS in PD. Further studies are needed to optimize the duration and exposure parameters of LT in the PD population.
Category - Sleep: Sleep & Neurodegenerative Disease
Tuesday, April 29, 2014 1:30 PM
S9: Platform Session: Sleep (1:00 PM-2:45 PM)